Communications scientifiques 2023

Articles

• Jooste V, Grosclaude P, Defossez G, Daubisse L, Woronoff AS, Bouvier V, Chirpaz E, Tretarre B, Lapotre B, Plouvier S, Launoy G, Bonneault M, Molinié F, Bouvier AM; FRANCIM Network. Net survival in colon and rectal cancer by stage according to neoadjuvant treatment. A French population-based study. Dig Liver Dis. 2023 Nov 3. Online ahead of print.
• Delacôte C, Ariza JM, Delacour-Billon S, Ayrault-Piault S, Borghi G, Menanteau K, Bouron A, Métais M, Cowppli-Bony A, Molinié F. Socioeconomic and geographic disparities of breast cancer incidence according to stage at diagnosis in France. Cancer Causes Control. 2023 Sep 11. Online ahead of print.
• Delacôte C, Delacour-Billon S, Ayrault-Piault S, Tagri AD, Rousseau G, Vincent M, Amossé S, Delpierre C, Cowppli-Bony A, Molinié F. Is survival rate lower after breast cancer in deprived women according to disease stage? Br J Cancer. 2023;128:63-70. Epub 2022 Nov 1.
• Poiseuil M, Payet C, Molinié F, Dabakuyo-Yonli TS, Mathoulin-Pelissier S, Amadeo B, Coureau G. Survival after breast cancer according to participation in organised or opportunistic screening and deprivation. Cancer Epidemiol. 2023;82:102312. Epub 2022 Dec 9.
• Trétarre B, Dantony E, Coureau G, Defossez G, Guizard AV, Delafosse P, Daubisse L, Velten M, Karima Hammas, Barra S, Lapotre B, Plouvier S, d’Almeida T, Molinié F, Woronoff AS. Trends in incidence of invasive vaginal cancer in France from 1990 to 2018 and survival of recently diagnosed women – A population-based study. Eur J Obstet Gynecol Reprod Biol. 2023;283:125-129.
• Lapôtre-Ledoux  B, Remontet  L, Uhry  Z, Dantony  E, Grosclaude P, Molinié F, et al. Incidence des principaux cancers en France métropolitaine en 2023 et tendances depuis 1990. Bull Épidémiol Hebd. 2023;(12-13):188-204.

Working groups :

FRANCIM

• Tron L, Remontet L, Fauvernier M, Rachet B, Belot A, Launay L, Merville O, Molinié F, Dejardin O, Francim Group, Launoy G.Cancers (Basel). Is the Social Gradient in Net Survival Observed in France the Result of Inequalities in Cancer-Specific Mortality or Inequalities in General Mortality? 2023 Jan 20;15:659.
• Gardy J, Wilson S, Guizard AV, Bouvier V, Tron L, Launay L, Alves A, On Behalf Of The Francim Group, Launoy G, Molinié F, Bryère J, Dejardin O. Cancer Survival and Travel Time to Nearest Reference Care Center for 10 Cancer Sites: An Analysis of 21 French Cancer Registries. Cancers (Basel). 2023;15(5):1516.

CONCORD

• Girardi F, Matz M, Stiller C, You H, Marcos Gragera R, Valkov MY, Bulliard JL, De P, Morrison D, Wanner M, O’Brian DK, Saint-Jacques N, Coleman MP, Allemani C; CONCORD Working Group. Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000-2014 (CONCORD-3). Neuro Oncol. 2023;25(3):580-592.

• Girardi F, Di Carlo V, Stiller C, Gatta G, Woods RR, Visser O, Lacour B, Tucker TC, Coleman MP, Allemani C; CONCORD Working Group. Global survival trends for brain tumors, by histology: Analysis of individual records for 67,776 children diagnosed in 61 countries during 2000-2014 (CONCORD-3). Neuro Oncol. 2023;25:593-606.

EUROCARE

• Demuru E, Rossi S, Ventura L, Dal Maso L, Guzzinati S, Katalinic A, Lamy S, Jooste V, Di Benedetto C, De Angelis R; EUROCARE-6 Working Group. Estimating complete cancer prevalence in Europe: validity of alternative vs standard completeness indexes. Front Oncol. 2023:13:1114701. eCollection 2023.